Literature DB >> 33586775

Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.

Janet D Siliciano1, Robert F Siliciano1,2.   

Abstract

The latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting CD4+ T cells is a major barrier to cure. The dimensions of the reservoir problem can be defined with 2 assays. A definitive minimal estimate of the frequency of latently infected cells is provided by the quantitative viral outgrowth assay (QVOA), which detects cells that can be induced by T-cell activation to release infectious virus. In contrast, the intact proviral DNA assay (IPDA) detects all genetically intact proviruses and provides a more accurate upper limit on reservoir size than standard single-amplicon polymerase chain reaction assays which mainly detect defective proviruses. The frequency of cells capable of initiating viral rebound on interruption of antiretroviral therapy lies between the values produced by the QVOA and the IPDA. We argue here that the 1-2-log difference between QVOA and IPDA values in part reflects that the fact that many replication-competent proviruses are not readily induced by T-cell activation. Findings of earlier studies suggest that latently infected cells can be activated to proliferate in vivo without expressing viral genes. The proliferating cells nevertheless retain the ability to produce virus on subsequent stimulation. The low inducibility of latent proviruses is a major problem for the shock-and-kill strategy for curing HIV-1 infection, which uses latency-reversing agents to induce viral gene expression and render infected cells susceptible to immune clearance. The latency-reversing agents developed to date are much less effective at reversing latency than T-cell activation. Taken together, these results indicate that HIV-1 eradication will require the discovery of much more effective ways to induce viral gene expression.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV-1; IPDA; QVOA; latent reservoir

Mesh:

Substances:

Year:  2021        PMID: 33586775      PMCID: PMC7883034          DOI: 10.1093/infdis/jiaa649

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  99 in total

1.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

2.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Authors:  Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho
Journal:  Cell Host Microbe       Date:  2017-04-12       Impact factor: 21.023

3.  Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane.

Authors:  Zheng Wang; Evelyn E Gurule; Timothy P Brennan; Jeffrey M Gerold; Kyungyoon J Kwon; Nina N Hosmane; Mithra R Kumar; Subul A Beg; Adam A Capoferri; Stuart C Ray; Ya-Chi Ho; Alison L Hill; Janet D Siliciano; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-26       Impact factor: 11.205

4.  Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.

Authors:  Deirdre D Scripture-Adams; David G Brooks; Yael D Korin; Jerome A Zack
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.

Authors:  Francesco R Simonetti; Michele D Sobolewski; Elizabeth Fyne; Wei Shao; Jonathan Spindler; Junko Hattori; Elizabeth M Anderson; Sarah A Watters; Shawn Hill; Xiaolin Wu; David Wells; Li Su; Brian T Luke; Elias K Halvas; Guillaume Besson; Kerri J Penrose; Zhiming Yang; Richard W Kwan; Carter Van Waes; Thomas Uldrick; Deborah E Citrin; Joseph Kovacs; Michael A Polis; Catherine A Rehm; Robert Gorelick; Michael Piatak; Brandon F Keele; Mary F Kearney; John M Coffin; Stephen H Hughes; John W Mellors; Frank Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

6.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

7.  Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.

Authors:  Yoshiki Koizumi; Hirofumi Ohashi; Syo Nakajima; Yasuhito Tanaka; Takaji Wakita; Alan S Perelson; Shingo Iwami; Koichi Watashi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

8.  The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.

Authors:  Alexandra M Bender; Francesco R Simonetti; Mithra R Kumar; Emily J Fray; Katherine M Bruner; Andrew E Timmons; Katherine Y Tai; Katharine M Jenike; Annukka A R Antar; Po-Ting Liu; Ya-Chi Ho; Dana N Raugi; Moussa Seydi; Geoffrey S Gottlieb; Afam A Okoye; Gregory Q Del Prete; Louis J Picker; Joseph L Mankowski; Jeffrey D Lifson; Janet D Siliciano; Greg M Laird; Dan H Barouch; Janice E Clements; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2019-07-10       Impact factor: 31.316

9.  An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Authors:  Gilles Darcis; Anna Kula; Sophie Bouchat; Koh Fujinaga; Francis Corazza; Amina Ait-Ammar; Nadège Delacourt; Adeline Melard; Kabamba Kabeya; Caroline Vanhulle; Benoit Van Driessche; Jean-Stéphane Gatot; Thomas Cherrier; Luiz F Pianowski; Lucio Gama; Christian Schwartz; Jorge Vila; Arsène Burny; Nathan Clumeck; Michel Moutschen; Stéphane De Wit; B Matija Peterlin; Christine Rouzioux; Olivier Rohr; Carine Van Lint
Journal:  PLoS Pathog       Date:  2015-07-30       Impact factor: 6.823

10.  New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

Authors:  C Korin Bullen; Gregory M Laird; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

View more
  4 in total

1.  HIV-1 gp120 Impairs Spatial Memory Through Cyclic AMP Response Element-Binding Protein.

Authors:  Jenny Shrestha; Maryline Santerre; Charles N S Allen; Sterling P Arjona; Carmen Merali; Ruma Mukerjee; Kumaraswamy Naidu Chitrala; Jin Park; Asen Bagashev; Viet Bui; Eliseo A Eugenin; Salim Merali; Marcus Kaul; Jeannie Chin; Bassel E Sawaya
Journal:  Front Aging Neurosci       Date:  2022-05-09       Impact factor: 5.702

2.  Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/β-catenin/TCF1 axis in CD4+ T cells.

Authors:  Jing Wen; Xin Li; Qing-Xia Zhao; Xiao-Fan Yang; Meng-Li Wu; Qihong Yan; Junbiao Chang; Haikun Wang; Xia Jin; Xiao Su; Kai Deng; Ling Chen; Jian-Hua Wang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

Review 3.  Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.

Authors:  Simone Belmonti; Simona Di Giambenedetto; Francesca Lombardi
Journal:  Diagnostics (Basel)       Date:  2021-12-24

Review 4.  Clonal Expansion of Infected CD4+ T Cells in People Living with HIV.

Authors:  John M Coffin; Stephen H Hughes
Journal:  Viruses       Date:  2021-10-15       Impact factor: 5.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.